Open wa­ter: NI­BR chief Jay Brad­ner part­ners with UC Berke­ley on pro­tein drug re­search in­sti­tute

Al­most ex­act­ly two years to the day since he was named head of the No­var­tis In­sti­tutes for Bio­Med­ical Re­search, Jay Brad­ner is cel­e­brat­ing the an­niver­sary with a new col­lab­o­ra­tion with top in­ves­ti­ga­tors at UC Berke­ley fo­cus­ing on pro­tein drug re­search.

In­spired by the land­mark al­liance with Penn that re­cent­ly led to the ap­proval of the world’s first CAR-T drug, Brad­ner is div­ing deep in­to a field he was al­ready im­mersed in as a re­searcher at Dana-Far­ber. In do­ing so he plans to take co­va­lent bind­ing to a whole new lev­el in search of new break­throughs that can start hit­ting some cur­rent­ly “un­drug­gable” tar­gets.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER